QUEST DIAGNOSTICS INC 8-K

What Happened

• Quest Diagnostics Inc. announced on April 27, 2026 that it priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036. The company entered into an underwriting agreement on April 27, 2026 with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC (and other underwriters). Quest expects to receive net proceeds at closing, which is anticipated on May 6, 2026, subject to customary closing conditions. A press release and the underwriting agreement were attached to the Form 8-K.

Key Details

• Offering size: $500 million aggregate principal amount.
• Coupon and maturity: 5.000% interest, due in 2036.
• Expected closing: May 6, 2026 (subject to customary conditions).
• Use of proceeds: General corporate purposes, which may include repaying the company’s $500 million of 3.45% Senior Notes that mature on June 1, 2026.

Why It Matters

• This is a financing action to raise cash for Quest Diagnostics’ near- and medium-term needs. The company may refinance a $500 million note maturing June 1, 2026, by replacing a 3.45% issue with a new 5.000% issue due 2036, which will change the company’s interest cost and maturity profile. Investors should note the timing (expected closing May 6, 2026) and that use of proceeds is flexible (general corporate purposes, including possible debt repayment).